Patients without baseline CNS metastases were randomly assigned ( @:@ ) to receive lapatinib-capecitabine ( lapatinib @,@ mg per day ; capecitabine @,@ mg/m ( @ ) per day on days @ to @ every @ days ) or trastuzumab-capecitabine ( trastuzumab loading dose of @ mg/kg followed by an infusion of @ mg/kg every @ weeks ; capecitabine @,@ mg/m ( @ ) per day on days @ to @ every @ days ) .